# EDGAR Filing Document

**Accession Number:** 0001751912
**File Stem:** 0001104659-26-001789
**Filing Date:** 2026-1
**Character Count:** 4488
**Document Hash:** dac0613474a6f954c14527fbd3c7489f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-001789.hdr.sgml**: 20260107

**ACCESSION NUMBER**: 0001104659-26-001789

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260107

**DATE AS OF CHANGE**: 20260107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NERVGEN PHARMA CORP.
- **CENTRAL INDEX KEY:** 0001751912
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43048
- **FILM NUMBER:** 26516056

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 1703 - 595 BURRARD STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V7X 1J1
- **BUSINESS PHONE:** 6047225361

**MAIL ADDRESS:**
- **STREET 1:** SUITE 1703 - 595 BURRARD STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V7X 1J1

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **WASHINGTON, DC 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES<br> PURSUANT TO SECTION 12(b) OR (g) OF THE<br> SECURITIES EXCHANGE ACT OF 1934**

**NERVGEN PHARMA CORP.**<br> (Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **British Columbia**<br> (State or other jurisdiction of incorporation or<br> organization) | **98-1738183**<br> (I.R.S. Employer Identification No.) |
| <br> **112-970 Burrard Street, Unit 1290<br> Vancouver, British Columbia, Canada**<br> (Address of principal executive offices) | <br>**V6Z 2R4**<br> (Zip Code) |

---

Securities to be registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class<br> to be so registered** | **Name of each exchange on which<br> each class is to be registered** |
| Common Shares, no par value per share | The Nasdaq Stock Market LLC<br>|

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ⌧

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ◻

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ◻

Securities Act registration statement or Regulation A offering statement file number to which this form relates: **333-292197**

Securities to be registered pursuant to Section 12(g) of the Act: **None**

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**Item 1. Description of Registrant's Securities to be Registered.**

The securities to be registered consist of common shares, no par value ("Common Shares") of NervGen Pharma Corp. (the "Registrant"). The description of the Registrant's Common Shares under the section captioned "Description of the Securities Being Distributed—Common Shares" in the short form base shelf prospectus included in the Registrant's registration statement on Form F-10 (File No. [333-292197](https://www.sec.gov/Archives/edgar/data/1751912/000110465925122026/tm2532520-1_f10.htm)) (the "Registration Statement"), filed with the Securities and Exchange Commission on December 17, 2025, is incorporated herein by reference. Any form of prospectus or prospectus supplement to the Registration Statement that includes such description and that are subsequently filed are hereby also incorporated by reference herein.

**Item 2. Exhibits.**

Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on the Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NERVGEN PHARMA CORP.** | **NERVGEN PHARMA CORP.** |
| Date: January 7, 2026 | By: | /s/ William J. Adams |
|  |  | William J. Adams<br> Chief Financial Officer |

---